 |
 |
 |
 |
 |
 |
About Cellerant |
|
Cellerant Therapeutics is a biotechnology company with a portfolio of products based on the regulation of the hematopoietic (blood-forming) system. The company focuses on curative therapies for seriously ill patients. Cellerant is developing a novel, cell-based medicine (Myeloid Progenitors / CLT-008) as a treatment for chemotherapy- and radiation-induced neutropenia as well as for Acute Radiation Syndrome. And we are applying our expertise in hematopoietic ontogeny to identify novel drug targets and therapeutic antibodies aimed at cancer stem cells. |
Cellerant in the News | ||
 |
|
May 13, 2009 Cellerant Therapeutics announces dosing of first patient in a Phase 1 trial of CLT-008 for hematological malignancies |
|
|
September 22, 2008 Cellerant Therapeutics Awarded $13.5 Million Contract for Treatment of Acute Radiation Syndrome From the Biomedical Advanced Research and Development Authority (BARDA) |
|
|
April 23, 2007 Cellerant Therapeutics Reversed Autoimmune Disease in Lupus Mice with Transplant of Purified Donor Blood Stem Cells |
|
|
December 12, 2006 Cellerant Therapeutics Presents Positive Preclinical Data on Purified Blood-Forming Stem Cells at ASH |
|
||
|
||
|
|
|